“South Africa is set to revolutionize HIV prevention with Aspen Pharmacare licensed to produce a once-a-month pill, alimatravir, even before trials conclude. This bold move, combined with the rollout of the six-monthly jab lenacapavir, could significantly reduce new infections and strengthen Africa’s pharmaceutical independence.”
South Africa, home to one of the world’s largest HIV epidemics, is witnessing a pivotal moment in its fight against the virus. With 140,000 new infections annually, the country has long sought innovative solutions to curb transmission. The latest development—a once-a-month HIV prevention pill, alimatravir (MK-8527), produced locally by Aspen Pharmacare—marks a turning point in both public health and pharmaceutical industrialization.
The Breakthrough
For the first time, Merck (MSD in South Africa) has granted generic licenses to manufacturers before clinical trials conclude. Aspen Pharmacare, South Africa’s largest drug maker, is among seven companies worldwide—three of them African—that received licenses. This unprecedented move allows factories to prepare production lines in advance, ensuring rapid availability once regulators approve the drug.
Why Choice Matters
The HIV prevention landscape has evolved from daily pills to long-acting injections. South Africa began rolling out lenacapavir (LEN), a six-monthly jab, in June 2026. Early uptake data suggests that the real breakthrough lies not in a single medicine but in offering multiple prevention options. For many, a monthly pill may be more practical than a biannual injection, while others prefer the convenience of fewer doses.
Economic and Industrial Impact
Producing alimatravir locally is more than a health intervention—it is a boost for Africa’s pharmaceutical industrialization. Aspen will import the active ingredient but assemble the pill in South Africa, enabling exports to 129 low- and middle-income countries, including all 54 African nations. This strengthens regional manufacturing capacity and reduces dependency on imports.
Affordability
A recent study estimates that generic alimatravir could cost $4.50 (R76) per person per year, making it significantly cheaper than lenacapavir. This affordability is crucial in scaling up prevention efforts across Africa, where millions remain at risk.
Risks and Challenges
Despite optimism, alimatravir is still in phase 3 clinical trials across 17 countries. Merck’s decision to license production early is a calculated risk, as efficacy and safety are not yet confirmed. Experts caution that large-scale adoption will require tens of millions of doses, a volume the HIV prevention market has yet to reach.
Global Context
The announcement comes amid the 26th International AIDS Conference in Rio de Janeiro, where global health leaders warned that the world is unlikely to meet the 2030 target of ending AIDS due to funding shortfalls. South Africa’s proactive stance contrasts sharply with global uncertainty, positioning the country as a leader in HIV prevention innovation.
Voices from the Field
Mitchell Warren, head of international HIV advocacy group Avac, praised Merck’s bold licensing strategy: “We don’t yet know if the medicine will work, but it’s a wise and strategically taken risk.” Stavros Nicolaou of Aspen highlighted the industrial significance: “This is a significant boost for Africa’s pharmaceutical ambitions.”
Conclusion
South Africa’s dual rollout of alimatravir and lenacapavir represents a paradigm shift in HIV prevention. By prioritizing choice, affordability, and local production, the country is not only tackling its epidemic but also reshaping Africa’s pharmaceutical future. If successful, this model could serve as a blueprint for other regions battling infectious diseases.
